Is dNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide inhibited by fludarabine and clofarabine?
DNA repair, which is active in CLL lymphocytes, may be a biological target for facilitating the incorporation of nucleoside analogues and increasing their cytotoxicity. Thus, the increased repair capacity associated with resistant disease may be manipulated to therapeutic advantage.
Lower admission serum calcium level is independently associated with HT after IVT, and this hypothesis needs larger confirmatory trials.